医疗设备数据安全信号检测的贝叶斯框架。

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Jianjin Xu, Adrijo Chakraborty, Archie Sachdeva, Ram Tiwari
{"title":"医疗设备数据安全信号检测的贝叶斯框架。","authors":"Jianjin Xu, Adrijo Chakraborty, Archie Sachdeva, Ram Tiwari","doi":"10.1080/10543406.2025.2464595","DOIUrl":null,"url":null,"abstract":"<p><p>Safety evaluation is important during both the pre-market clinical trials and post-market surveillance. In either a pre-market or post-market setting wherein the safety of a device is compared to that of a control device, it is desirable to identify any difference in the safety between two devices as expeditiously as possible. Here, we introduce the Bayesian hierarchical framework for the safety assessment in two-arm clinical trials, with signal detection accomplished by evaluating the effect size of each adverse event (AE) measured by odds ratio or relative risk. The framework starts with a standard hierarchical Bayesian model with a parametric distribution as a common prior for the effect sizes of all AEs. Then, it is extended with a non-parametric prior, Dirichlet Process Prior, to allow for more flexibility. After that, to account for the rare events in some trials, it is further extended with the option of additional zero-inflated parameters and calculation of regularized effect size. Extra incorporation of exposure-time information is available under each framework. The performance of the proposed technique, along with its extensions, is studied by simulation. The application of the proposed Bayesian framework is demonstrated by data from a two-device clinical trial, the newer left ventricular assist device (LVAD) and the existing LVAD. The Bayesian analysis result is then compared to a traditional frequentist technique. Through both simulation and application, the proposed Bayesian technique is shown to be robust to the selection of priors of the variance component, and has comparative and under some scenarios even better performance than the frequentist technique. Overall, the developed Bayesian framework is a feasible alternative to the frequentist method for safety evaluation of medical device clinical trials.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-17"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Bayesian framework for safety signal detection from medical device data.\",\"authors\":\"Jianjin Xu, Adrijo Chakraborty, Archie Sachdeva, Ram Tiwari\",\"doi\":\"10.1080/10543406.2025.2464595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Safety evaluation is important during both the pre-market clinical trials and post-market surveillance. In either a pre-market or post-market setting wherein the safety of a device is compared to that of a control device, it is desirable to identify any difference in the safety between two devices as expeditiously as possible. Here, we introduce the Bayesian hierarchical framework for the safety assessment in two-arm clinical trials, with signal detection accomplished by evaluating the effect size of each adverse event (AE) measured by odds ratio or relative risk. The framework starts with a standard hierarchical Bayesian model with a parametric distribution as a common prior for the effect sizes of all AEs. Then, it is extended with a non-parametric prior, Dirichlet Process Prior, to allow for more flexibility. After that, to account for the rare events in some trials, it is further extended with the option of additional zero-inflated parameters and calculation of regularized effect size. Extra incorporation of exposure-time information is available under each framework. The performance of the proposed technique, along with its extensions, is studied by simulation. The application of the proposed Bayesian framework is demonstrated by data from a two-device clinical trial, the newer left ventricular assist device (LVAD) and the existing LVAD. The Bayesian analysis result is then compared to a traditional frequentist technique. Through both simulation and application, the proposed Bayesian technique is shown to be robust to the selection of priors of the variance component, and has comparative and under some scenarios even better performance than the frequentist technique. Overall, the developed Bayesian framework is a feasible alternative to the frequentist method for safety evaluation of medical device clinical trials.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2025.2464595\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2464595","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

安全性评价在上市前临床试验和上市后监测中都很重要。在上市前或上市后的环境中,将器械的安全性与控制器械的安全性进行比较,希望尽可能快地识别两种器械之间的安全性差异。在这里,我们引入了贝叶斯层次框架,用于两组临床试验的安全性评估,通过评估每个不良事件(AE)的效应大小(以优势比或相对风险衡量)来完成信号检测。该框架从一个标准的分层贝叶斯模型开始,该模型将参数分布作为所有ae效应大小的共同先验。然后,用非参数先验,狄利克雷过程先验进行扩展,以允许更大的灵活性。之后,为了考虑某些试验中的罕见事件,进一步扩展了附加零膨胀参数选项和正则化效应大小的计算。在每个框架下都可以获得额外的曝光时间信息。通过仿真研究了该技术及其扩展的性能。贝叶斯框架的应用通过双装置临床试验的数据来证明,新型左室辅助装置(LVAD)和现有的左室辅助装置。然后将贝叶斯分析结果与传统的频率分析技术进行比较。仿真和应用结果表明,贝叶斯方法对方差分量先验选择具有较强的鲁棒性,在某些情况下性能优于频域方法。总体而言,所开发的贝叶斯框架是一种可行的替代频率方法,用于医疗器械临床试验的安全性评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Bayesian framework for safety signal detection from medical device data.

Safety evaluation is important during both the pre-market clinical trials and post-market surveillance. In either a pre-market or post-market setting wherein the safety of a device is compared to that of a control device, it is desirable to identify any difference in the safety between two devices as expeditiously as possible. Here, we introduce the Bayesian hierarchical framework for the safety assessment in two-arm clinical trials, with signal detection accomplished by evaluating the effect size of each adverse event (AE) measured by odds ratio or relative risk. The framework starts with a standard hierarchical Bayesian model with a parametric distribution as a common prior for the effect sizes of all AEs. Then, it is extended with a non-parametric prior, Dirichlet Process Prior, to allow for more flexibility. After that, to account for the rare events in some trials, it is further extended with the option of additional zero-inflated parameters and calculation of regularized effect size. Extra incorporation of exposure-time information is available under each framework. The performance of the proposed technique, along with its extensions, is studied by simulation. The application of the proposed Bayesian framework is demonstrated by data from a two-device clinical trial, the newer left ventricular assist device (LVAD) and the existing LVAD. The Bayesian analysis result is then compared to a traditional frequentist technique. Through both simulation and application, the proposed Bayesian technique is shown to be robust to the selection of priors of the variance component, and has comparative and under some scenarios even better performance than the frequentist technique. Overall, the developed Bayesian framework is a feasible alternative to the frequentist method for safety evaluation of medical device clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信